RWMG
AKBA icon

Redwood Wealth Management Group’s Akebia Therapeutics AKBA Stock Holding History

Redwood Wealth Management Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-300
Closed -$306 – 191
2024
Q2 		$306 Buy
+300
New +$371 ﹤0.01% 1092

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Redwood Wealth Management Group's AKBA Position: Q3 2024 in Review

Redwood Wealth Management Group sold out of Akebia Therapeutics (AKBA) in Q3 2024, closing a stake of 300 shares — an estimated $306 sold.

Redwood Wealth Management Group first reported a position in AKBA in Q2 2024 and held it in 1 quarter. The position peaked at $306 in Q2 2024. 114 funds tracked by Wall St. Rank hold AKBA as of Q3 2024.

  • Redwood Wealth Management Group reported no remaining Akebia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Redwood Wealth Management Group sold 300 Akebia Therapeutics shares in Q3 2024, an estimated $306.
  • Redwood Wealth Management Group first reported a position in Akebia Therapeutics in Q2 2024 and held it in 1 quarter.
  • Redwood Wealth Management Group's Akebia Therapeutics position peaked at $306 in Q2 2024.
  • 114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2024.

Based on Redwood Wealth Management Group's 13F filing for Q3 2024, filed 13 Nov 2024.